Xilio Therapeutics Statistics

Total Valuation

XLO has a market cap or net worth of $38.34 million. The enterprise value is -$58.17 million.

Market Cap	38.34M
Enterprise Value	-58.17M

Important Dates

The last earnings date was Thursday, November 13, 2025, before market open.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

XLO has 52.50 million shares outstanding. The number of shares has increased by 17.23% in one year.

Current Share Class	52.50M
Shares Outstanding	52.50M
Shares Change (YoY)	+17.23%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	13.86%
Owned by Institutions (%)	13.15%
Float	25.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.19
Forward PS	1.09
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.20

Current Ratio	2.20
Quick Ratio	2.15
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-437.75

Financial Efficiency

Return on equity (ROE) is -908.28% and return on invested capital (ROIC) is -191.61%.

Return on Equity (ROE)	-908.28%
Return on Assets (ROA)	-26.26%
Return on Invested Capital (ROIC)	-191.61%
Return on Capital Employed (ROCE)	-56.64%
Revenue Per Employee	$496,938
Profits Per Employee	-$913,891
Employee Count	64
Asset Turnover	0.31
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.12% in the last 52 weeks. The beta is -0.05, so XLO's price volatility has been lower than the market average.

Beta (5Y)	-0.05
52-Week Price Change	-30.12%
50-Day Moving Average	0.78
200-Day Moving Average	0.76
Relative Strength Index (RSI)	44.89
Average Volume (20 Days)	648,738

Short Selling Information

The latest short interest is 6.91 million, so 13.17% of the outstanding shares have been sold short.

Short Interest	6.91M
Short Previous Month	6.16M
Short % of Shares Out	13.17%
Short % of Float	26.87%
Short Ratio (days to cover)	7.80

Income Statement

In the last 12 months, XLO had revenue of $31.80 million and -$58.49 million in losses. Loss per share was -$1.13.

Revenue	31.80M
Gross Profit	26.26M
Operating Income	-43.78M
Pretax Income	-58.49M
Net Income	-58.49M
EBITDA	-42.18M
EBIT	-43.78M
Loss Per Share	-$1.13

Full Income Statement

Balance Sheet

The company has $103.76 million in cash and $7.26 million in debt, giving a net cash position of $96.50 million or $1.84 per share.

Cash & Cash Equivalents	103.76M
Total Debt	7.26M
Net Cash	96.50M
Net Cash Per Share	$1.84
Equity (Book Value)	-8.10M
Book Value Per Share	-0.16
Working Capital	67.69M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$17.15 million and capital expenditures -$429,000, giving a free cash flow of -$17.58 million.

Operating Cash Flow	-17.15M
Capital Expenditures	-429,000
Free Cash Flow	-17.58M
FCF Per Share	-$0.33

Full Cash Flow Statement

Margins

Gross margin is 82.57%, with operating and profit margins of -137.64% and -183.90%.

Gross Margin	82.57%
Operating Margin	-137.64%
Pretax Margin	-183.90%
Profit Margin	-183.90%
EBITDA Margin	-132.63%
EBIT Margin	-137.64%
FCF Margin	n/a

Dividends & Yields

XLO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.23%
Shareholder Yield	-17.23%
Earnings Yield	-152.57%
FCF Yield	-45.86%

Analyst Forecast

The average price target for XLO is $2.00, which is 173.90% higher than the current price. The consensus rating is "Buy".

Price Target	$2.00
Price Target Difference	173.90%
Analyst Consensus	Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	2.47%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

XLO has an Altman Z-Score of -4.56 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.56
Piotroski F-Score	4